Aqualung Therapeutics
Manufacturing · Arizona, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
6080 N Pinchot Rd, Tucson, Arizona, 8575...Website
www.aqualungtherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Aqualung Therapeutics
Aqualung Therapeutics, Corp is a biotech company based in Tucson, AZ and Jupiter, FL, focused on developing novel therapies for immune-driven diseases. They have created ALT-100, an anti-eNAMPT monoclonal antibody aimed at treating serious inflammatory, fibrotic, and autoimmune disorders. The company has published peer-reviewed research demonstrating the efficacy of ALT-100 in various preclinical models, including conditions like Acute Respiratory Distress Syndrome and Prostate Cancer. Their target clients include patients suffering from a range of inflammatory and fibrotic diseases.Explore more
Aqualung Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aqualung Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Aqualung Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Aqualung Therapeutics recently announced quarterly report
Aqualung Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Aqualung Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Aqualung Therapeutics
Check out if Aqualung Therapeutics is spiking on competitors!
Check if Aqualung Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Aqualung Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined Aqualung Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Aqualung Therapeutics
Compare insights from companies similar to Aqualung Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aqualung Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aqualung Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aqualung Therapeutics.
Aqualung Therapeutics Tech Stack
A closer look at the technologies used by Aqualung Therapeutics
Aqualung Therapeutics News & Media
Aqualung Therapeutics Receives FDA Clearance for Phase 2a Lung Fibrosis Study
JUNO BEACH, Fla., Dec. 22, 2025 /PRNewswire/ -- Aqualung Therapeutics, a clinical-stage immunotherapeutics company, announced today that the Food and Drug Administration (FDA) has cleared its Phase 2a study of ALT-100 mAb as an anti-inflammatory and anti-fibrotic therapy in human subjects...First in Human Subjects Enrolled in Aqualung Therapeutics Phase 1A Study Evaluating Safety, Tolerability and Pharmacokinetics of ALT-100
TUCSON, AZ / ACCESSWIRE / July 5, 2022 / Aqualung Therapeutics, an early stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for serious unchecked inflammatory disorders, announced today that their first two patients have been enrolled in the phase 1A healthy human volunteer Study. The data from this study will be used to understand and validate dosing and safety of the humanized monoclonal antibody therapeutic ALT-100 for future clinical trials that addAqualung Therapeutics Appoints Two New Board Directors; Will Attend June 22 Bio Meeting in San Diego
TUCSON, AZ / ACCESSWIRE / June 8, 2022 / Aqualung Therapeutics, an early stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for serious unchecked inflammatory disorders, unanimously appointed two highly accomplished entrepreneurs and scientists to the recently formed Aqualung Therapeutics Board of Directors. Industry experts Donald Payan MD and Robert Schleimer PhD will officially begin their Board tenure in June.Aqualung Therapeutics Selected to Present at the Phoenix 2021 Venture Madness Competition on October 6-7th
TUCSON, AZ / ACCESSWIRE / August 23, 2021 / Aqualung Therapeutics, an early-stage biotech company developing an immune-focused, anti-inflammatory therapeutic platform for unchecked inflammation, is excited to be one of 5 medical companies selected to present at the 2021 Annual Southwest Venture Madness competition. There were over 120 companies who submitted applications for this year's competition.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aqualung Therapeutics
Sign Up For FreeTo access detailed company insights
Aqualung Therapeutics, Corp is a biotech company based in Tucson, AZ and Jupiter, FL, focused on developing novel therapies for immune-driven diseases. They have created ALT-100, an anti-eNAMPT monoclonal antibody aimed at treating serious inflammatory, fibrotic, and autoimmune disorders. The company has published peer-reviewed research demonstrati... Read More
